Breaking News, Financial News

Financial Report: Alexion 2Q11

Soliris sales jump 48% to $185.7 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion 2Q11 2Q Revenues: $186.0 million (+48%) 2Q Earnings: $34.7 million (+60%) YTD Revenues: $352.0 million (+45%) YTD Earnings: $61.6 million (+4%) Comments: Sales of Soliris (eculizumab) were up 48% to $185.7 million in the quarter. R&D expenses for the quarter were $35.6 million, up 50%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters